GSK’s Rotarix U.S. Launch Scheduled For Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves the two-dose rotavirus vaccine, which will compete against Merck’s three-dose vaccine, RotaTeq.
You may also be interested in...
FDA Panel Votes To Clear GlaxoSmithKline Rotavirus Vaccine For Approval
GSK’s Rotarix gets nod from FDA’s Vaccines and Related Biological Products Advisory Committee.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.